Attend CED's next Biotech Forum to hear experts discuss the ins and outs of adaptive clinical studies including:
• How to save time and costs
• The benefits of adaptive trial design
• Regulatory issues
• Virtual models vs. Build-out models
• Strategies to get trials complete and on time while getting good data
Michael Rosenberg, MD, MPH, president and CEO, Health Decisions, Inc. will explore the what, when and why of adaptive clinical studies at the September 22 Biotech Forum. Subsequently, a premier line-up of panelists will discuss how to choose the best trial, tricks of the trade, and how to choose a Contract Research Organization (CRO).
CED's Biotech Forum: Clinical Trials - Adaptive Trial Design & Best Practices in Clinical Development Strategies
Date: Monday, September 22, 2008
Time: 4:30 - 8:00 p.m.
Location: North Carolina Biotech Center, Research Triangle Park, NC - Directions
Fees: $25 CED Members / $40 Non-members ($45 on-site)
Seating is limited - register today - www.cednc.org/btforum
Featured Panelists Include (partial list):
• Vipin K. Garg, Ph.D., president and CEO, Tranzyme Pharma Inc.
• Moise A. Khayrallah, Ph.D., CEO and co-founder, Addrenex Pharmaceuticals, Inc
• Michael Rosenberg, MD, MPH, president and chief executive officer, Health Decisions, Inc.
• Nadia Rupniak, Ph.D., vice president, research and development, CoLucid Pharmaceuticals, Inc.
• Drusilla Scott, Ph.D., R.A.C., senior vice president, regulatory affairs, Cempra Pharmaceuticals, Inc.
For more information, contact Elizabeth Call at 919.549.7500 ext.130 or visit www.cednc.org/btforum